CBP-201 is an extremely potent monoclonal antibody against IL-4Rα, a receptor found on immune cells that mediates the biological activities of both IL-4 and IL-13, two important cytokines that drive allergic inflammation such as asthma and atopic dermatitis. Extensive preclinical and clinical studies have shown that blocking IL-4Rα reduces inflammation in a wide variety of allergic inflammatory conditions.  CBP-201 was discovered internally and is wholly-own by Connect.

TEL/FAX: 0512-53577866

E-MAIL: qchang@connectpharm.com

ADD: Science and Technology Park, East R&D Building , 3rd Floor , 6 Beijing West Road, Taichang, Jiangsu, China 215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.

Technical support: Epower